- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05344508
An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
February 20, 2024 updated by: Insmed Incorporated
Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis
The purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.
Study Overview
Status
Available
Conditions
Intervention / Treatment
Detailed Description
Participants will receive brensocatib 10 mg, oral tablets, once daily.
Study Type
Expanded Access
Expanded Access Type
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
- Participant had agreed to provide their informed consent to participate per local requirements.
- Participant had successfully completed Clinical Trial INS 1007-301 ASPEN, including the End of study Visit 12 prior to receiving treatment.
- Requests for Post-Trial access for brensocatib had come from ASPEN investigator.
- Had received brensocatib treatment.
Exclusion Criteria:
- Participant had experienced a serious adverse event deemed to be related to brensocatib during the study and required permanent participant is continuation.
- The participant is immunocompromised or chronically treated with any investigational or commercialized immunomodulatory agent that is directed to any component of the adaptive or innate immune systems.
Note: The use of any immunomodulatory agents (including but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, IFN-γ, and azathioprine) is prohibited during the program.
- The participant had undergone continuous use of high dose non-steroidal anti-inflammatory drugs.
- The participant had undergone chronic use of systemic steroids for any chronic condition, except steroids with topical anti-inflammatory activities (ie, oral budesonide).
- Participant had planned to receive live attenuated vaccines during the program (treatment must be postponed until 4 weeks after the last dose of drug).
- Participant had planned to use investigational drugs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 6, 2022
First Submitted That Met QC Criteria
April 18, 2022
First Posted (Actual)
April 25, 2022
Study Record Updates
Last Update Posted (Actual)
February 21, 2024
Last Update Submitted That Met QC Criteria
February 20, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INS1007-EAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Cystic Fibrosis Bronchiectasis
-
Papworth Hospital NHS Foundation TrustLifeArcNot yet recruitingNon-cystic Fibrosis BronchiectasisUnited Kingdom
-
The University of Hong KongRecruiting
-
The University of Hong KongCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Assiut UniversityNot yet recruitingNon-cystic Fibrosis Bronchiectasis
-
Mayo ClinicRecruitingNon-cystic Fibrosis BronchiectasisUnited States
-
AstraZenecaActive, not recruitingNon-cystic Fibrosis BronchiectasisUnited States, Canada, Denmark, Germany, Italy, United Kingdom, Vietnam, China, Spain, Korea, Republic of, Argentina, Australia, Poland, Russian Federation, Philippines, India
-
Boehringer IngelheimCompletedNon-cystic Fibrosis BronchiectasisUnited Kingdom, Germany
-
All India Institute of Medical Sciences, New DelhiCompletedNon-cystic Fibrosis BronchiectasisIndia
-
Hospital Clinic of BarcelonaSociedad Española de Neumología y Cirugía TorácicaUnknownNon-cystic Fibrosis Bronchiectasis
Clinical Trials on Brensocatib
-
Insmed IncorporatedCompletedNon-Cystic Fibrosis BronchiectasisUnited States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
-
Insmed IncorporatedActive, not recruitingNon-Cystic Fibrosis BronchiectasisNew Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
-
Insmed IncorporatedCompleted
-
Insmed IncorporatedCompletedRenal ImpairmentUnited States
-
University of DundeeNHS Tayside; Insmed IncorporatedCompletedCovid19United Kingdom
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Insmed IncorporatedCompletedCystic FibrosisUnited States
-
Insmed IncorporatedCompletedHealthy VolunteersUnited States
-
Insmed IncorporatedCompleted
-
Insmed IncorporatedCompletedHealthy VolunteersUnited States